Tel：
(86)(21)60969600
Add: Building 28, Lane 588, Tianxiong Road. Shanghai, P. R. China
Recently, the 22nd Atrial Fibrillation Forum (CAFS 2024) was successfully held in Dalian, Liaoning Province. This conference provided a comprehensive platform for communication, discussion and learning through multi-dimensional special forums and sessions. Domestic and international experts gathered to share academic achievements in atrial fibrillation and promote the progress of basic and clinical research on atrial fibrillation in China.
During the conference, Shanghai MicroPort EP MedTech Co., Ltd. (referred to as "MicroPort EP") held an academic symposium titled "Ice, Fire, Electricity - Comprehensive Electrophysiological Solution". Professor Yao Yan from Fuwai Hospital, Chinese Academy of Medical Sciences, Professor Gao Lianjun from the First Affiliated Hospital of Dalian Medical University, Professor Wang Zulu from the General Hospital of Northern Theater Command and Professor Fu Hua from West China Hospital of Sichuan University were specially invited to serve as the chairpersons of the symposium. Professor Yu Bo from the First Affiliated Hospital of China Medical University, Professor Li Shaolong from Yan'an Hospital Affiliated to Kunming Medical University and Professor Song Xudong from Zhujiang Hospital of Southern Medical University were specially invited to serve as the hosts of the symposium. They exchanged and discussed the clinical application experience of the IceMagic™ CryoAblation Catheter (Multi-channel Temperature Measurement Type) (referred to as "IceMagic™ CryoAblation Catheter") and the FireMagic™ TrueForce™ Ablation Catheter (referred to as "TrueForce™ Ablation Catheter") as well as the clinical progress of electrophysiological pulsed field ablation (PFA) with many domestic electrophysiological experts.
Professor Fu Hua from West China Hospital of Sichuan University made an in-depth report on the topic of "Characteristics of the Second-generation IceMagic™ CryoAblation Catheter and Its Application in Atrial Fibrillation", and introduced the excellent performance of the IceMagic™ CryoAblation Catheter in detail through several clinical cases, especially its outstanding advantages in temperature control and safety. Professor Fu Hua pointed out that the IceMagic™ CryoAblation Catheter has strong adherence and precise temperature control ability, improving the safety and effectiveness of the surgery. In addition, he also mentioned that the cryoablation technology of MicroPort EP has not only made breakthroughs in operational convenience but also performed well in clinical applications. Domestic electrophysiological treatment technology is developing rapidly, and it is expected to bring good news to more patients with atrial fibrillation in the future.
During the discussion session, Professor Zhou Wei from the Affiliated Hospital of Guizhou Medical University and Professor Cheng Guanghui from Wuhan Asia Heart Hospital made comments and additions. Professor Zhou Wei particularly emphasized the high efficiency and safety of the IceMagic™ CryoAblation Catheter in clinical applications. He said that the excellent performance of the catheter in actual operations increased the success rate of the surgery and reduced the incidence of complications, improving the treatment experience of patients. Professor Cheng Guanghui further added that the maneuverability and accuracy of the catheter in actual surgeries made the entire surgical process more smooth, shortening the operation time and the recovery period of patients.
Professor Ding Ligang from Fuwai Hospital, Chinese Academy of Medical Sciences, pointed out in "Preliminary Experience of TrueForce™ Ablation Catheter in Paroxysmal Atrial Fibrillation" that the EasyStars™ High Density Mapping Catheter can quickly and accurately construct the left atrial model. The TrueForce™ Ablation Catheter provides real-time and precise force value feedback, and the Energy Index (EI) index provides reliable ablation parameters for physicians, which helps evalsuate the ablation effect and thereby improves the ablation efficiency.
Professor Zhao Liang from Shanghai Chest Hospital and Professor Liu Yang from Guangdong Provincial People's Hospital unanimously highly recognized the application of the TrueForce™ Ablation Catheter in the treatment of complex arrhythmia diseases such as atrial fibrillation and expressed their pleasure to see the continuous innovation and progress of domestic medical devices.
Professor Wang Zulu from the General Hospital of Northern Theater Command explained the clinical progress of electrophysiological pulsed field ablation (PFA) and shared cases with the participating experts through the topic of "New Multi-loop Circular Electrode and Pulsed Field Ablation System for the Treatment of Paroxysmal Atrial Fibrillation". Professor Wang Zulu pointed out that the treatment success rate within 12 months after pulsed ablation was relatively high, the incidence of major adverse events was extremely low, the safety was high, and it largely shortened the operation time and reduced the exposure time of X-rays.
Professor Ding Ligang from Fuwai Hospital, Chinese Academy of Medical Sciences, mentioned in the communication that pulsed ablation is a better ablation energy with a short operation time and can better serve clinical practice. Professor Zeng Rui from West China Hospital of Sichuan University made a detailed interpretation of the clinical results and highly evalsuated the ablation rate and efficiency of the catheter.
At the end of the conference, Professor Gao Lianjun, the chairperson of the symposium, said in his speech that as a domestic electrophysiological manufacturer, MicroPort EP can provide a comprehensive and integrated electrophysiological solution, bringing more affordable treatment options for domestic patients with atrial fibrillation and complex arrhythmia diseases. He expected that MicroPort EP could develop more and better products in the future to benefit more patients.
This conference fully demonstrated the empowerment of technological innovation to clinical diagnosis and treatment, making it safer, more precise and more efficient. Different ablation techniques have their unique advantages in surgical operation, energy transmission, catheter design, etc., which can help physicians provide personalized treatment plans for patients. Currently, MicroPort EP has achieved the coordinated development of "radiofrequency + cryoablation" two major ablation energy products. The TrueForce™ Ablation Catheter and the IceMagic™ Cryoablation System have respectively become the first domestic pressure catheter and the first domestic cryoablation system. The pulsed field ablation series products have entered the pre-market clinical follow-up stage, which will provide a more comprehensive solution for the treatment of atrial fibrillation in clinical practice.
In the future, MicroPort EP will continue to forge ahead on the path of academic sharing and scientific research innovation, provide patients and doctors with more perfect products and professional services, and provide an electrophysiological interventional diagnosis and treatment integrated solution with global competitiveness.
